Building the Domestic Market for Ferinject 500 mg Intravenous Injection
First written in FY2019. 7 of 9 entries say "Restated". Latest entry: FY2023-Q3.
5 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on the gastroenterology and obstetrics and gynecology fields.」
The company continues to build the domestic market for Ferinject, focusing primarily on the gastroenterology and obstetrics and gynaecology fields. - FY2023-Q2RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on the gastroenterology and obstetrics and gynecology fields.」
The company continues to build the domestic market for Ferinject, focusing primarily on the gastroenterology and obstetrics and gynaecology fields. - FY2023-Q1RestatedAnnual report
「The company is working to develop the markets for Acofide and Ferinject, focusing respectively on medical institutions that perform endoscopies and on gastroenterology and obstetrics and gynecology departments.」
The company continues to build the domestic market for Ferinject, focusing primarily on gastroenterology and obstetrics and gynaecology. - FY2022-Q3RestatedAnnual report
「Ferinject, which was launched in Japan in September 2020, is being developed in the market, focusing primarily on gastroenterology and obstetrics and gynaecology.」
Following Ferinject's launch in Japan, the company continues to build the market, focusing primarily on gastroenterology and obstetrics and gynaecology. - FY2022-Q2RestatedAnnual report
「Ferinject, which was launched in Japan in September of the previous year, is being developed in the market, focusing primarily on gastroenterology and obstetrics and gynaecology.」
Following Ferinject's launch in Japan, the company continues to build the market, focusing primarily on gastroenterology and obstetrics and gynaecology. - FY2022-Q1RestatedAnnual report
「Ferinject I.V. 500 mg, a treatment for iron-deficiency anaemia launched in Japan in September of the previous year, is being developed in the market, focusing primarily on gastroenterology and obstetrics and gynaecology.」
Following Ferinject's launch in Japan, the company continues to build the market, focusing primarily on gastroenterology and obstetrics and gynaecology. - FY2021-Q2AdvancedAnnual report
「Ferinject I.V. 500 mg, a treatment for iron-deficiency anaemia, was launched in Japan in September 2020. The company expects the product to benefit patients as a new treatment option for iron-deficiency anaemia.」
Ferinject I.V. 500 mg was launched in Japan in September 2020, moving into the sales phase following approval as the company works to build the domestic market. - FY2020RestatedAnnual report
「In addition, Ferinject I.V. 500 mg was promptly listed for reimbursement, and we will work to build the market, focusing primarily on obstetrics and gynaecology and gastroenterology.」
The company continues to target prompt reimbursement listing for Ferinject and market building focused primarily on obstetrics and gynaecology and gastroenterology. - FY2019First statedAnnual report
「For Ferinject I.V. 500 mg, a treatment for iron-deficiency anaemia approved in Japan in March 2019, the company will work to build the market at an early stage, focusing primarily on obstetrics and gynaecology and gastroenterology.」
The company explicitly stated for the first time its plan to build the market early for the new product following approval in Japan, focusing primarily on obstetrics and gynaecology and gastroenterology.